Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Open-label pharmacokinetic study of TS-142 (vornorexant) in patients with hepatic impairment
jRCT2031220463Phase 1Completed
- Sponsor
- Taisho Pharmaceutical
- Start
- Dec 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of vornorexant in Insomnia (3 arms), sponsored by Taisho Pharmaceutical. Primary endpoint: Plasma concentration of unchanged form and its metabolites. Started Dec 2022; status: completed.
02
Drugs
vornorexant
03
Conditions
Insomnia
Beyond the preview
Go deeper on jRCT2031220463.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031220463.